- Policy
- MFDS reviews EUA of COVID-19 prevention drug Evusheld
- by Lee, Hye-Kyung Jun 14, 2022 06:04am
- The emergency use authorization review for AstraZeneca’s COVID-19 preventive antibody therapy ‘Evusheld’ has begun in Korea. The Ministry of Food and Drug Safety (Minister Yu-Kyoung Oh) announced on the 10th that the ministry has started reviewing the emergency use authorization of Evusheld per request by the Korea Disease Control and
- Policy
- Yoon Gov should increase bio-health investment by 15% per yr
- by Lee, Jeong-Hwan Jun 14, 2022 06:04am
- Professor Park Eun-chul said, "We need to provide intensive support for disaster medical expenses after breaking away from the Moon administration." In order for the Yoon Seok-yeol government to innovate health care, it was suggested that the bio-health government's investment ratio should be drastically increased by more than 15% every ye
- Policy
- A petition has been filed for public consent to Enhurtu
- by Lee, Jeong-Hwan Jun 13, 2022 05:55am
- A petition for public consent has been filed to urge the health insurance coverage of HER2 (Human Epithelial Cell Growth Factor Receptor 2) low-expression breast cancer treatment Enhurtu, which is set to be approved for marketing in Korea. The petitioner, who recently filed a petition through the National Assembly, introduced to the Yoon Seok
- Policy
- Novartis' new adult leukemia drug Scemblix has been approved
- by Lee, Hye-Kyung Jun 13, 2022 05:54am
- Scemblix, a treatment for Ph+ CML adult patients, has obtained domestic permission. The MFDS approved Scemblix 20mg and Scemblix 40mg applied by Novartis on the 9th. Scemblix is used in the treatment of chronic Ph+ CML adult patients who have previously been treated with two or more TKI. The efficacy was based on MMR and Cytogenetic Re
- Policy
- The risk group for COVID-19 depression was 18.5%, down
- by Lee, Jeong-Hwan Jun 13, 2022 05:54am
- The COVID-19 depression risk group surveyed in the first quarter of this year was 18.5%, down from 22.8% in March last year. It is still high compared to 3.2% in 2019, before COVID-19, and the government plans to push for COVID-19 psychological support for daily recovery. On the 3rd, the MOHW made the announcement at a regular briefing on COV
- Policy
- Govt skeptical about using existing vaccines on monkeypox
- by Lee, Jeong-Hwan Jun 9, 2022 06:25am
- The government has said that the use of licensed human smallpox vaccines, antivirals, or vaccinia immune globulin intravenous (VIGIV) to prevent the domestic outbreak of monkeypox should be carefully considered in terms of efficacy and safety. In particular, the authorities explained there is a plan to study whether the 3rd generation sma
- Policy
- Cases for Pre-approval of Ultomiris exceeds 100
- by Lee, Tak-Sun Jun 9, 2022 06:25am
- The number of approved Ultomiris administered was 101 until April. Ultomiris, a treatment for paroxysmal nocturnal hemoglobinuria (PNH), has been shown to have completely replaced Soliris, the existing treatment since its benefits in June last year. Both are expensive rare drugs, and must be approved in advance by the Board of Review
- Policy
- Monkeypox becomes Class 2 infectious disease in Korea
- by Lee, Jeong-Hwan Jun 9, 2022 06:24am
- The viral zoonosis monkeypox will be designated and managed as a ‘Class 2 infectious disease’ by law starting today (8th). With its level raised, monkeypox will now be managed and considered to have the same level of risk as COVID-19, tuberculosis, and chickenpox. If a person is confirmed with a Class 2 infectious disease, this mus
- Policy
- Evusheld is expected to be introduced this month
- by Lee, Jeong-Hwan Jun 9, 2022 06:24am
- The government is expected to introduce Evusheld, a COVID-19 antibody treatment that is administered to patients who do not form antibodies well even with vaccinations, to Korea this month. Lee Ki-il, the first general coordinator of the Central Disaster and Safety Countermeasures Headquarters, presided over a meeting at the Sejong Governm
- Policy
- Bringing 3rd gen monkeypox vaccine to Korea in discussion
- by Lee, Jeong-Hwan Jun 8, 2022 05:56am
- The government announced on the 7th that it has started discussions on the quantity and schedule for bringing a ‘3rd generation monkeypod vaccine’ to Korea with its manufacturer. The authorities decided to accelerate the introduction of this third-generation vaccine with proven efficacy as the number of confirmed cases of monkeypox cont
